share_log

Tonix Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

SEC ·  Nov 12, 2024 22:14

Summary by Futu AI

Tonix Pharmaceuticals reported Q3 2024 financial results with net revenue of $2.8 million and a net loss of $14.2 million, compared to revenue of $4.0 million and a net loss of $28.0 million in Q3 2023. Research and development expenses decreased 57% to $9.1 million, while selling, general and administrative expenses declined 11% to $7.7 million. The company recorded $1.7 million in grant income during the quarter.The company's cash position stood at $28.2 million as of September 30, 2024. During Q3, Tonix raised approximately $41.8 million through ATM offerings and an additional $3.5 million through a securities purchase agreement. The company expects current cash resources to fund operations into Q1 2025 but will require additional financing to continue operations beyond that point.Tonix's lead program TNX-102 SL for fibromyalgia received FDA Fast Track designation in Q3 2024, with an NDA submitted in October 2024. The company expects an FDA decision on NDA acceptance and PDUFA date in December 2024. Additionally, Tonix secured a DTRA contract worth up to $34 million over five years to develop TNX-4200, a broad-spectrum antiviral agent targeting CD45.
Tonix Pharmaceuticals reported Q3 2024 financial results with net revenue of $2.8 million and a net loss of $14.2 million, compared to revenue of $4.0 million and a net loss of $28.0 million in Q3 2023. Research and development expenses decreased 57% to $9.1 million, while selling, general and administrative expenses declined 11% to $7.7 million. The company recorded $1.7 million in grant income during the quarter.The company's cash position stood at $28.2 million as of September 30, 2024. During Q3, Tonix raised approximately $41.8 million through ATM offerings and an additional $3.5 million through a securities purchase agreement. The company expects current cash resources to fund operations into Q1 2025 but will require additional financing to continue operations beyond that point.Tonix's lead program TNX-102 SL for fibromyalgia received FDA Fast Track designation in Q3 2024, with an NDA submitted in October 2024. The company expects an FDA decision on NDA acceptance and PDUFA date in December 2024. Additionally, Tonix secured a DTRA contract worth up to $34 million over five years to develop TNX-4200, a broad-spectrum antiviral agent targeting CD45.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 581

Recommended